Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial

Summary Background In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo. Here we present the prospectively defined analyses of some secondary endpoi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2014-09, Vol.15 (10), p.1147-1156
Hauptverfasser:	Fizazi, Karim, Prof, Scher, Howard I, Prof, Miller, Kurt, Prof, Basch, Ethan, MD, Sternberg, Cora N, MD, Cella, David, Prof, Forer, David, MSc, Hirmand, Mohammad, MD, de Bono, Johann S, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Androgens Bone Neoplasms - drug therapy Bone Neoplasms - mortality Bone Neoplasms - secondary Cancer therapies Confidence Intervals Disease-Free Survival Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Follow-Up Studies Fractures Hematology, Oncology and Palliative Medicine Humans Inventory Kaplan-Meier Estimate Male Maximum Tolerated Dose Men Mens health Metastasis Middle Aged Mortality Neoplasm Invasiveness - pathology Pain Pain Management - methods Patients Phenylthiohydantoin - adverse effects Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - therapeutic use Proportional Hazards Models Prospective Studies Prostate cancer Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - mortality Prostatic Neoplasms, Castration-Resistant - pathology Quality of Life Risk Assessment Studies Survival Analysis Treatment Outcome Voice recognition
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!